Managing Partner
Dr. Alon Lazarus joined Arkin Bio in 2013 as a Managing Partner. He serves on the board of several of Arkin’s pharmaceutical companies, including Bluejay Therapeutics, Enact Bio, Auron Therapeutics, Modal Therapeutics and Werewolf Therapeutics (NASDAQ: HOWL). Dr. Lazarus has led investments in pharmaceutical companies, from early stages through public offerings in the U.S.
In his previous endeavors, Dr. Lazarus worked in the healthcare business development department of Yissum, the R&D arm of the Hebrew University of Jerusalem.
Dr. Lazarus holds a Ph.D. in Molecular Biology and an MBA, both from the Hebrew University of Jerusalem.
Let’s get in touch!
